Here are a couple of analogies for Astrotech (ASTC):

• A high-tech Smiths Detection, focused on building advanced mass spectrometry scanners for airports and borders.

• A specialized Thermo Fisher Scientific, developing unique mass spectrometry instruments for markets like cannabis testing and breath analysis.

• AMS Technology: A platform mass spectrometry technology owned and licensed by Astrotech Technologies, Inc.
• TRACER 1000: A mass spectrometer-based explosives trace detector used at airports, cargo, and secured facilities.
• AgLAB-1000: A mass spectrometer developed for use in the hemp and cannabis market.
• BreathTest-1000: A breath analysis tool designed to screen for volatile organic compound metabolites in a person's breath.

Astrotech (ASTC) primarily sells its products to other companies, government entities, and institutions, rather than directly to individuals. Based on the company description, its major customer categories are:

1. Government and Security Agencies: These include entities responsible for security at airports, national borders, and other secured facilities. This category would encompass government agencies (e.g., transportation security authorities, customs and border protection), airport operating authorities, and large security service providers that manage such facilities. They purchase explosives and narcotics trace detectors (TRACER 1000).
2. Hemp and Cannabis Businesses: Companies operating within the legal hemp and cannabis market, such as cultivators, processors, and independent testing laboratories, are customers for the AgLAB-1000 mass spectrometer, which is designed for quality control and analysis in this industry.
3. Healthcare, Research, and Corporate Entities: For its BreathTest-1000 device, potential customers include healthcare providers (e.g., clinics, hospitals), medical research institutions, and possibly corporations or government programs for health screening or monitoring purposes.

Thomas B. Pickens, III, Chief Executive Officer and Chairman of the Board

Mr. Pickens has served as the Chief Executive Officer of Astrotech Corporation since January 2007. He also serves as CEO of Astrotech's subsidiaries: Astrotech Technologies Inc, 1st Detect, AgLAB Inc., and BreathTech Corporation. Prior to his current role, Mr. Pickens founded and served as President of Beta Computer Systems, Inc. from 1982 to 1984, and founded and was President of T.B. Pickens & Co. from 1985 to 1995. Astrotech's management, including Mr. Pickens, sold Astrotech Space Operations to Lockheed Martin in August 2014.

Scott Bartley, Interim Chief Financial Officer

Mr. Bartley was appointed Interim Chief Financial Officer, effective October 20, 2025. He possesses over two decades of experience as a controller and CFO across various industries. Since 2011, Mr. Bartley has worked as a financial consultant, offering accounting, reporting, fundraising, and audit support to both public and private companies, including a role as a consultant at Bridgepoint Consulting since 2018. He was also the owner and managing director of Tolarus Partners from 2013 to 2015 and Helix Advisors from 2011 to 2013 and again from 2015 to 2018, where he provided contract CFO and valuation services. From 2008 to 2011, he served as CFO of Westlake Securities, a broker-dealer, and previously was an Assurance Senior Manager at Deloitte & Touche, LLP. Mr. Bartley is a Certified Public Accountant and Certified Valuation Analyst.

Nihanth Badugu, Chief Operating Officer

Mr. Badugu was appointed Chief Operating Officer, effective August 13, 2025. He joined Astrotech in August 2023 as the Director of Program Management, where he concentrated on initiatives to enhance operational efficiency and ensure the successful completion of various programs.

Joe Levinthal, Chief Science Officer of AgLAB Inc.

Mr. Levinthal serves as the Chief Science Officer of AgLAB Inc., one of Astrotech's segments.

David Spada, Director of Global Sales, 1st Detect Corporation

Mr. Spada was appointed Director of Global Sales for Astrotech's subsidiary, 1st Detect Corporation, on January 21, 2026. He brings over a decade of specialized trace detection expertise to the role.

1. Dependence on Successful Commercialization and Market Adoption of Novel Technologies: Astrotech's business model hinges on the successful development, regulatory approval, and widespread market acceptance of its mass spectrometry-based products across its subsidiaries. This includes the TRACER 1000 for explosives and narcotics detection, AgLAB-1000 for the hemp and cannabis market, and BreathTest-1000 for breath analysis. Product development inherently involves a high degree of risk and uncertainty, with no guarantee that these new products will achieve full market authorization or be commercially successful. For example, while the TRACER 1000 has received certifications and is deployed internationally and in cargo facilities, it has not yet been deployed at U.S. passenger screening checkpoints, which is a significant market. Similarly, the AgLAB-1000 targets the hemp and cannabis market, which is subject to evolving and inconsistent regulations. The BreathTest-1000, designed for medical screening, faces a complex and lengthy FDA approval process, with few breath tests having been approved in recent decades.


2. Intense Competition from Established Players: Astrotech operates in markets with significant competition from larger, more established companies that may possess greater financial resources, broader product portfolios, and entrenched market positions. In the explosive trace detection market, major competitors include Smiths Detection, Leidos, OSI Systems, and Bruker, among others. These competitors are well-established and continue to innovate, offering advanced solutions that integrate new sensors, AI analytics, and comprehensive after-sales service networks. Astrotech's 1st Detect subsidiary aims for its TRACER 1000 to "replace" existing detectors, indicating a direct challenge to these incumbents, which can be difficult in a market that often requires substantial testing, certification, and long sales cycles.


3. Significant Financial and Operating Losses: Astrotech has a history of incurring significant losses since its inception and anticipates continued losses for the foreseeable future. The company's business units are in the development stage with limited revenues, requiring substantial funding to commercialize products. For instance, Astrotech reported a net loss of $13.9 million for the fiscal year ending June 30, 2025, with revenues of only $1.0 million. This low revenue base, combined with significant and sustained cash burn from high operating and R&D expenses, creates a reliance on future funding, potentially leading to equity dilution if new product lines do not generate revenue quickly.

Astrotech Corporation (ASTC) operates in several markets with its main products and services:

1st Detect Segment: TRACER 1000 (Explosives and Narcotics Trace Detector)

• The global explosive trace detection market size was valued at approximately USD 1.62 billion in 2025 and is projected to grow to USD 2.88 billion by 2034, at a compound annual growth rate (CAGR) of 6.40% from 2026 to 2034. North America accounted for the largest market share in 2025. Another estimate places the global explosive trace detection market size at USD 6.92 billion in 2024, projected to reach USD 12.96 billion by 2035, growing at a CAGR of 6.48% from 2025 to 2035.

AgLAB Segment: AgLAB-1000 (Mass Spectrometer for Hemp and Cannabis Market)

• The global cannabis testing services market size was estimated at USD 2.68 billion in 2025 and is projected to reach approximately USD 7.22 billion by 2035, expanding at a CAGR of 10.42% from 2026 to 2035. North America held the largest revenue share in the global cannabis testing services market in 2025.

AgLAB Segment: BreathTest-1000 (Breath Analysis Tool for Volatile Organic Compound Metabolites)

• The global Breath VOC Diagnostics Platforms market size reached USD 410.6 million in 2024. This market is projected to grow at a CAGR of 17.3% from 2025 to 2033, reaching a forecasted value of USD 1,509.8 million by the end of 2033. North America remains the leading market for Breath VOC Diagnostics Platforms. For broader context, the global breath analyzers market, which includes medical applications, was estimated at USD 2.75 billion in 2022 and is projected to reach USD 9.3 billion by 2030, growing at a CAGR of 16.6% from 2023 to 2030.

1. Expanded Deployment and Global Reach of TRACER 1000: The TRACER 1000, a mass spectrometer-based explosives and narcotics trace detector, is a significant growth driver. Astrotech's subsidiary, 1st Detect, is actively expanding its global footprint, with the TRACER 1000 deployed in approximately 35 locations across 16 countries, and has appointed a Director of Global Sales to further this expansion. A major opportunity lies in supporting the U.S. Department of Homeland Security's (DHS) $1 billion aviation security modernization initiative, which could lead to substantial deployments at U.S. passenger checkpoints upon completion of TSA approval processes for cargo security. The launch of an enhanced TRACER 1000 Narcotics Trace Detector also addresses the growing need for detecting synthetic drugs, presenting further market penetration opportunities.
2. Growth of the EN-SCAN Product Line: The newly formed EN-SCAN subsidiary and its product line of portable environmental testing instruments are poised for revenue growth. These instruments offer real-time, on-site analysis for air, water, and soil, enabling quicker data-driven decisions and reducing traditional lab testing times and costs. The company is actively transitioning from product development to sales for the EN-SCAN Handheld GC and other related solutions, indicating an expectation of increased market adoption.
3. Commercialization of AgLAB-1000 in the Hemp and Cannabis Market: Astrotech's AgLAB segment continues to focus on the production and sales efforts for the AgLAB-1000, a mass spectrometer specifically designed for the hemp and cannabis market. This product targets a rapidly expanding, multi-billion-dollar industry, offering a significant avenue for future revenue generation.
4. Launch and Adoption of Pro-Control-1000 for Chemical Manufacturing: The company established a new subsidiary, Pro-Control, Inc., in late 2023, to commercialize the Pro-Control-1000 mass spectrometer. This instrument is designed for in-situ chemical manufacturing process control, aiming to enhance potency, purity, and yields. This diversification into industrial manufacturing markets is expected to contribute to future revenue.
5. Development and Potential Approval of BreathTest-1000: Astrotech is developing the BreathTest-1000, a breath analysis tool for screening volatile organic compound metabolites. This product targets the medical diagnostics market, which represents a significant multi-billion-dollar opportunity. While currently requiring FDA approval, successful commercialization of this innovative diagnostic tool could be a substantial future revenue driver.

Share Repurchases

• Astrotech made minor share repurchases amounting to $0.12 million in fiscal year 2022.

Share Issuance

• Astrotech issued approximately $67.58 million in common stock during fiscal year 2021.
• A 1-for-30 reverse stock split was completed retroactively at June 30, 2025, consolidating the number of shares outstanding.

Outbound Investments

• The company made purchases of investments totaling approximately $5.14 million in fiscal year 2022.
• Astrotech announced the creation of EN-SCAN, Inc., a new wholly-owned subsidiary focused on manufacturing and selling instruments, on February 28, 2025.

Capital Expenditures

• Capital expenditures were approximately $0.83 million in fiscal year 2025, $0.58 million in fiscal year 2024, $1.84 million in fiscal year 2023, $0.60 million in fiscal year 2022, and $0.21 million in fiscal year 2021.
• A new Austin facility lease has contractual base rent obligations of about $3.0 million, impacting fixed-cost commitments.